Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jul;118(6):1409–1414. doi: 10.1111/j.1476-5381.1996.tb15553.x

Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels.

E J Hide 1, C Thiemermann 1
PMCID: PMC1909684  PMID: 8832065

Abstract

1. This study examined whether (i) a 1 h pretreatment with or (ii) a continuous infusion of sulprostone reduces myocardial infarct size arising from coronary artery occlusion (60 min) and reperfusion (120 min) in the anaesthetized rabbit. In addition, we investigated whether the observed cardioprotective effect of this selective agonist of prostanoid EP1/EP3 receptors were due to the activation of ATP-sensitive potassium (KATP) channels. 2. In anaesthetized rabbits pretreated with vehicle (5% ethanol in 0.9% saline; 0.05 ml min-1, i.v.) infarct size (expressed as a percentage of the area at risk) after 60 min of coronary artery occlusion followed by 120 min of reperfusion was 59 +/- 4% (n = 10). Pretreatment of rabbits with sulprostone (1.0 microgram kg-1 min-1 for 1 h, discontinued immediately prior to coronary artery occlusion) did not reduce infarct size (60 +/- 4%; n = 4). In contrast, a continuous infusion of sulprostone (1.0 microgram kg-1 min-1) starting 10 min prior to the onset of LAL occlusion and continued throughout the experiment, significantly reduced infarct size (41 +/- 5%, n = 6) when compared to the respective vehicle-treated controls (57 +/- 4%, n = 10; P < 0.05). Sulprostone (pretreatment or continuous infusion) had no effect on any of the haemodynamic parameters measured. 3. The reduction in infarct size afforded by continuous infusion of sulprostone was abolished by pretreatment of rabbits with the KATP channel blocker 5-hydroxydecanoate (5-HD 5 micrograms kg-1; 63 +/- 4%; n = 6). When administered alone, 5-HD had no effect on infarct size when compared to control (52 +/- 6, n = 10). 4. We propose that a continuous infusion of the selective EP1/EP3 prostanoid receptor agonist, sulprostone, reduces infarct size in the anaesthetized rabbit by a mechanism that involves the opening of KATP channels.

Full text

PDF
1409

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araki H., Lefer A. M. Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res. 1980 Nov;47(5):757–763. doi: 10.1161/01.res.47.5.757. [DOI] [PubMed] [Google Scholar]
  2. Ashby B. Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors. Second Messengers Phosphoproteins. 1988;12(1):45–57. [PubMed] [Google Scholar]
  3. Auchampach J. A., Grover G. J., Gross G. J. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res. 1992 Nov;26(11):1054–1062. doi: 10.1093/cvr/26.11.1054. [DOI] [PubMed] [Google Scholar]
  4. Auchampach J. A., Maruyama M., Cavero I., Gross G. J. The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther. 1991 Dec;259(3):961–967. [PubMed] [Google Scholar]
  5. Baller D., Bretschneider H. J., Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol. 1981 Mar-Apr;76(2):163–181. doi: 10.1007/BF01907955. [DOI] [PubMed] [Google Scholar]
  6. Coleman R. A., Kennedy I., Sheldrick R. L. New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:467–470. [PubMed] [Google Scholar]
  7. Flores N. A., Davies R. L., Penny W. J., Sheridan D. J. Coronary microangiography in the guinea pig, rabbit and ferret. Int J Cardiol. 1984 Oct;6(4):459–471. doi: 10.1016/0167-5273(84)90326-7. [DOI] [PubMed] [Google Scholar]
  8. Goto M., Liu Y., Yang X. M., Ardell J. L., Cohen M. V., Downey J. M. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995 Sep;77(3):611–621. doi: 10.1161/01.res.77.3.611. [DOI] [PubMed] [Google Scholar]
  9. Grover G. J., Dzwonczyk S., Parham C. S., Sleph P. G. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther. 1990 Apr;4(2):465–474. doi: 10.1007/BF01857755. [DOI] [PubMed] [Google Scholar]
  10. Grover G. J., McCullough J. R., Henry D. E., Conder M. L., Sleph P. G. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Ther. 1989 Oct;251(1):98–104. [PubMed] [Google Scholar]
  11. Grover G. J., Sleph P. G., Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation. 1992 Oct;86(4):1310–1316. doi: 10.1161/01.cir.86.4.1310. [DOI] [PubMed] [Google Scholar]
  12. Grundemar L., Jonas S. E., Mörner N., Högestätt E. D., Wahlestedt C., Håkanson R. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol. 1992 Jan;105(1):45–50. doi: 10.1111/j.1476-5381.1992.tb14208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hide E. J., Ney P., Piper J., Thiemermann C., Vane J. R. Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 1995 Nov;116(5):2435–2440. doi: 10.1111/j.1476-5381.1995.tb15092.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hide E. J., Piper J., Thiemermann C. Endothelin-1-induced reduction of myocardial infarct size by activation of ATP-sensitive potassium channels in a rabbit model of myocardial ischaemia and reperfusion. Br J Pharmacol. 1995 Nov;116(6):2597–2602. doi: 10.1111/j.1476-5381.1995.tb17213.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hutton I., Parratt J. R., Lawrie T. D. Cardiovascular effects of prostaglandin E 1 in experimental myocardial infarction. Cardiovasc Res. 1973 Mar;7(2):149–155. doi: 10.1093/cvr/7.2.149. [DOI] [PubMed] [Google Scholar]
  16. Jugdutt B. I., Hutchins G. M., Bulkley B. H., Becker L. C. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res. 1981 Sep;49(3):685–700. doi: 10.1161/01.res.49.3.685. [DOI] [PubMed] [Google Scholar]
  17. Katoh H., Watabe A., Sugimoto Y., Ichikawa A., Negishi M. Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochim Biophys Acta. 1995 May 11;1244(1):41–48. doi: 10.1016/0304-4165(94)00182-w. [DOI] [PubMed] [Google Scholar]
  18. Lindner V., Heinle H. Binding properties of circulating Evans blue in rabbits as determined by disc electrophoresis. Atherosclerosis. 1982 Jun;43(2-3):417–422. doi: 10.1016/0021-9150(82)90040-5. [DOI] [PubMed] [Google Scholar]
  19. Liu G. S., Thornton J., Van Winkle D. M., Stanley A. W., Olsson R. A., Downey J. M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991 Jul;84(1):350–356. doi: 10.1161/01.cir.84.1.350. [DOI] [PubMed] [Google Scholar]
  20. Lopaschuk G. D., Michalak M., Wandler E. L., Lerner R. W., Piscione T. D., Coceani F., Olley P. M. Prostaglandin E receptors in cardiac sarcolemma. Identification and coupling to adenylate cyclase. Circ Res. 1989 Sep;65(3):538–545. doi: 10.1161/01.res.65.3.538. [DOI] [PubMed] [Google Scholar]
  21. Matthews J. S., Jones R. L. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol. 1993 Feb;108(2):363–369. doi: 10.1111/j.1476-5381.1993.tb12810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Maxwell M. P., Hearse D. J., Yellon D. M. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res. 1987 Oct;21(10):737–746. doi: 10.1093/cvr/21.10.737. [DOI] [PubMed] [Google Scholar]
  23. McCullough J. R., Normandin D. E., Conder M. L., Sleph P. G., Dzwonczyk S., Grover G. J. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res. 1991 Oct;69(4):949–958. doi: 10.1161/01.res.69.4.949. [DOI] [PubMed] [Google Scholar]
  24. Murry C. E., Jennings R. B., Reimer K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124–1136. doi: 10.1161/01.cir.74.5.1124. [DOI] [PubMed] [Google Scholar]
  25. NACHLAS M. M., SHNITKA T. K. Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. Am J Pathol. 1963 Apr;42:379–405. [PMC free article] [PubMed] [Google Scholar]
  26. Parratt J. R., Kane K. A. KATP channels in ischaemic preconditioning. Cardiovasc Res. 1994 Jun;28(6):783–787. doi: 10.1093/cvr/28.6.783. [DOI] [PubMed] [Google Scholar]
  27. Qian Y. M., Jones R. L., Chan K. M., Stock A. I., Ho J. K. Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol. 1994 Oct;113(2):369–374. doi: 10.1111/j.1476-5381.1994.tb16997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Riemersma R. A., Talbot R. C., Ungar A., Mjøs O. D., Oliver M. F. Effects of prostaglandin-E1 on ST segment elevation and regional myocardial blood flow during experimental myocardial ischaemia in dogs. Eur J Clin Invest. 1977 Dec;7(6):515–521. doi: 10.1111/j.1365-2362.1977.tb01645.x. [DOI] [PubMed] [Google Scholar]
  29. Schrör K., Thiemermann C., Ney P. Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation. Naunyn Schmiedebergs Arch Pharmacol. 1988 Sep;338(3):268–274. doi: 10.1007/BF00173399. [DOI] [PubMed] [Google Scholar]
  30. Simpson P. J., Mickelson J., Fantone J. C., Gallagher K. P., Lucchesi B. R. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. J Pharmacol Exp Ther. 1988 Feb;244(2):619–624. [PubMed] [Google Scholar]
  31. Talpain E., Armstrong R. A., Coleman R. A., Vardey C. J. Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br J Pharmacol. 1995 Apr;114(7):1459–1465. doi: 10.1111/j.1476-5381.1995.tb13370.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Thiemermann C., Thomas G. R., Vane J. R. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. Br J Pharmacol. 1989 Jun;97(2):401–408. doi: 10.1111/j.1476-5381.1989.tb11967.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thornton J. D., Liu G. S., Olsson R. A., Downey J. M. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation. 1992 Feb;85(2):659–665. doi: 10.1161/01.cir.85.2.659. [DOI] [PubMed] [Google Scholar]
  34. Toombs C. F., Moore T. L., Shebuski R. J. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 1993 Apr;27(4):617–622. doi: 10.1093/cvr/27.4.617. [DOI] [PubMed] [Google Scholar]
  35. Vegh A., Papp J. G., Szekeres L., Parratt J. R. Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning? Cardiovasc Res. 1993 Apr;27(4):638–643. doi: 10.1093/cvr/27.4.638. [DOI] [PubMed] [Google Scholar]
  36. Walsh R. S., Tsuchida A., Daly J. J., Thornton J. D., Cohen M. V., Downey J. M. Ketamine-xylazine anaesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res. 1994 Sep;28(9):1337–1341. doi: 10.1093/cvr/28.9.1337. [DOI] [PubMed] [Google Scholar]
  37. Wheeldon A., Vardey C. J. Characterization of the inhibitory prostanoid receptors on human neutrophils. Br J Pharmacol. 1993 Apr;108(4):1051–1054. doi: 10.1111/j.1476-5381.1993.tb13504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wise H., Jones R. L. Characterization of prostanoid receptors on rat neutrophils. Br J Pharmacol. 1994 Oct;113(2):581–587. doi: 10.1111/j.1476-5381.1994.tb17029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ytrehus K., Liu Y., Downey J. M. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994 Mar;266(3 Pt 2):H1145–H1152. doi: 10.1152/ajpheart.1994.266.3.H1145. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES